A randomized phase II trial showed an improvement in tumor response rate and overall survival for the antibody–drug conjugate trastuzumab deruxtecan (T-DXd) compared with standard chemotherapy in patients with pretreated HER2-positive advanced gastric cancer [66]. Here, ERBB2 is linked to gastric cancer.